MUCOSINT

Multifunctional Composite Silica Nanotubes for Targeted Delivery

Coordinatore	GAZI UNIVERSITESI    more  Organization address address: GAZI UNIVERSITESI GOLBASI YERLESKESI NANOTIP ARASTIRMA MERKEZI BAHCELIEVLER MAHALLESI 160 city: ANKARA postcode: 6830 contact info Titolo: Dr. Nome: Gurer G. Cognome: Budak Email: send email Telefono: 903125000000 Fax: 903125000000
Nazionalità Coordinatore	Turkey [TR]
Totale costo	75˙000 €
EC contributo	75˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2009-RG
Funding Scheme	MC-IRG
Anno di inizio	2010
Periodo (anno-mese-giorno)	2010-01-01   -   2012-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	GAZI UNIVERSITESI  Organization address address: GAZI UNIVERSITESI GOLBASI YERLESKESI NANOTIP ARASTIRMA MERKEZI BAHCELIEVLER MAHALLESI 160 city: ANKARA postcode: 6830 contact info Titolo: Dr. Nome: Gurer G. Cognome: Budak Email: send email Telefono: 903125000000 Fax: 903125000000	TR (ANKARA)	coordinator	75˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Multifunctional nanoparticles hold great promise in targeted therapy as well as other biotechnological fields such as biomolecule sensing and cell separation. The potential of these particles to controllably deliver and accumulate therapeutic and diagnostic agents to target sites in the body make them especially useful platforms for the research in various disease types. Ideal particles for these applications should be easy to synthesize, have minimal size variation and hold efficient functionalities. Combining all these properties in the nanoscale level, however, is a formidable challenge. This project proposes a new class of non-spherical nanoparticles called Multifunctional Composite Silica Nanotubes (MuCoSiNT) for targeted therapeutic delivery applications. MuCoSiNTs will be fabricated by a facile synthesis method that allows absolute control over particle dimensions and functionalities. Moreover, they comprise large inner voids that will be filled with a composite gel matrix for the targeted delivery of imaging and therapeutic agents at high payload capacities. The in vitro cytotoxicities and antitumor activities of these particles will be determined by examining their effect on cellular viabilities and growth inhibition profiles. Finally, MuCoSiNT internalization into the cells and consequent morphological changes will be confirmed using microscopic techniques.'